CD70 antibody (CD70 Molecule) (PE) Primary Antibody
- This CD70 antibody is conjugated to PE
- Flow Cytometry (FACS)
- The mouse monoclonal antibody Ki-24 recognizes CD70, an approximately 50 kDa type II transmembrane glycoprotein expressed on activated lymphocytes and some B cell leukemias.
Workshop Code: IV A109
- Cross-Reactivity (Details)
- Alternative Name
- CD70 (CD70 Antibody Abstract)
- CD70, also known as TNFSF7 or CD27L, is a 50 kDa type II transmembrane glycoprotein of the TNF superfamily. It is expressed mainly on activated lymphocytes, including NK cells, and forms trimeric structure. CD70 plays a role in T-cell activation, proliferation and differentiation, in enhancing the generation of cytolytic T cells, and in long-term maintenance of T cell memory. It is also involved in B cell differentiation induced by activated plasmacytoid dendritic cells, which also express CD70.
- Gene ID
- Cancer Immune Checkpoints
- Application Notes
- The reagent is designed for Flow Cytometry analysis of human blood cells using 10 μ,l reagent / 100 μ,l of whole blood or 106 cells in a suspension.The content of a vial (1 ml) is sufficient for 100 tests.
The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
- For Research Use only
- The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15 mM sodium azide.
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 4 °C
- Storage Comment
- Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Trebing, El-Mesery, Schäfer, Weisenberger, Siegmund, Silence, Wajant: "CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants." in: Cell death & disease, Vol. 5, pp. e1035, 2014 (PubMed).
Hashimoto-Okada, Kitawaki, Kadowaki, Iwata, Morimoto, Hori, Uchiyama: "The CD70-CD27 interaction during the stimulation with dendritic cells promotes naive CD4(+) T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans." in: International immunology, Vol. 21, Issue 8, pp. 891-904, 2009 (PubMed).
Kaufmann, Amariglio, Rosenthal, Hirsch, Many, Rechavi: "Proliferation response of leukemic cells to CD70 ligation oscillates with recurrent remission and relapse in a low-grade lymphoma." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 10, pp. 6940-7, 2005 (PubMed).
Israel, Pickles, Segal, Gerard, Kenney: "Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody." in: Journal of virology, Vol. 75, Issue 11, pp. 5215-21, 2001 (PubMed).
- Trebing, El-Mesery, Schäfer, Weisenberger, Siegmund, Silence, Wajant: "CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants." in: Cell death & disease, Vol. 5, pp. e1035, 2014 (PubMed).